


Focus & Delivery

Special General Meeting
June 23, 2016



Simavita

Meeting Agenda

- COMPANY UPDATE
- TECHNOLOGY UPDATE
- RESOLUTIONS

Forward Looking Statements

This presentation may contain “forward-looking information” within the meaning of Canadian securities laws (“forward-looking information”). This forward-looking information is given as of the date of this document.


Forward-looking information relates to future events or future performance and reflects Simavita management’s expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct.

In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or information that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology.

By its very nature, forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita’s interim and annual financial statements and management’s discussion and analysis of those statements.

Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.

What this Special General Meeting of Shareholders Delivers



Funding enables Simavita to reorganise and refocus on delivery

- Reorganise with a significantly paired down cost structure - focused on sales
- Deliver product mix which is fit for, and demanded by, the market
 - Peel & Apply sensors
 - Cheaper, simpler and easier to use product
- Enables the Company to build from a very low base of sales BUT with a very different management structure and new product mix
- Maintain geographic focus on ANZ, US and EU
- Delivers a very real message to the market – Simavita shareholders believe in our product and our opportunity
- In due course the Company will seek any remaining balance of \$10m funding from new investors


The Board's Fee Pool

- The Board of Directors NOT looking to increase directors fees
- One additional director may be added shortly to fill Audit & Risk requirements
- When and only when, the Company has demonstrably proven that it has turned the corner, we will at that time look for additional and outstanding Board candidates

Incoming Directors Options

- Incoming Directors are absolutely aligned with shareholders
- Directors are focused and intent on delivering
- We are opening doors, involved in restructuring, engaged daily
- Actively assisting executive management
- Eliminated the immediate and significant costs associated with a new MD and CFO

Early goals




We're working hard


- The pain of restructuring was delivered early
 - 40% reduction in peak headcount and costs, focused on non sales related activity
 - Further reduction in costs associated with
 - Sydney office accommodation
 - De-listing from TSX-V
 - Constant cost control at all levels
- Critical assessment of product and market opportunity - particularly in light of past performance
- The Executive Team is committed to building a sales led organisational structure
- Reorganisation activity leading increasingly toward better service at lower cost

A Flat Organisational Structure

- Each segment of the business has a responsibility based budget and delivery target
- All business segments have direct reports into the Board of Directors
- No MD or CFO at present



Simavita - A Market Facing Organisation



Our assessment of what's gone wrong


- Single product company not reflective of a large and modestly complex market need
- Successful users are highly committed and prepared to invest

SIM™ Product Sales Life Cycle

Long Lead Times

Reducing Use

High Maintenance



Our assessment of market needs

- One size does not fit all:
 - High end aged care
 - Tight margin business needs
 - Reduced costs associated with disposables
 - Regulatory compliance
 - Ease of use & time saving
 - Rehabilitation and institutional need
 - Very low cost “alert” product
 - Reduced COGS with greater flexibility
- Ease of use, training and implementation
- Real cost and real time savings
- Emerging regulatory/accreditation regimes and government initiatives

SIM™ System

Assess Plus

Alert

Peel & Apply



Products must match market demand

MARKET

High End Aged Care

High Throughput Rehab/Hospitals
Low Cost Aged Care Compliance

Assisted Living Community & Low Cost Every Day

MARKET SIZE

High Margin
Low Volume

Good Margin
Significant Volume

Low Margin
Substantial Volume

SIMAVITA PRODUCT

SIM™ System

New Product Assess Plus
DELIVERY DATE END Q3 2016

New Product Alert
TBA

Peel & Apply


Super cheap sensor



Our Imperative – Prove the business

- Prove there is a substantial and sustainable business
- Step wise increase in revenue and gross margin
- Major account sales focus – targeted selling, performance measured, transformational
- Partnership management in key existing and new markets
- New product lines including - **Assess Plus** and **Peel & Apply** technology aimed squarely at reduced costs, sales time, account maintenance, greater customer use as a product that delivers cost reduction and time saving. Much easier to use and install.
- Continued focus on cost control
- Open engagement with our stakeholders

Technology Review
Innovation Briefing - Peter Curran




Roadmap, short term

Project	Key Drivers	Deliverable	Timing
SIM™ 4.12	Advanced care planning; Rehab & Hospital, interoperability; cloud based; leverage IP	Release	June '16
Assess Plus New Product	Rapid low cost deployment and support; ease of use; supports new markets	Release	Q3 2016
Peel & Apply Sensor	Lower Cost & diaper agnostic	Release	Q3 2016
Hospital & Rehab	New revenue stream	Available now	Available now
Community	New revenue stream	Assess Plus & Alert	See above

Drivers

- Evidence based solutions
- Support our Value Proposition
 - Deliver better care
 - Improved health economics – Lowering product and operational costs
 - Lowering risks
- Simplicity and convenience
- Lower cost of goods
- Support new revenue streams
- Leverage market experience




Product differentiation


	SIM™ system	Assess Plus
Assessment	✓	✓
Care Planning	✓	✓
Stand-alone operation		✓
Enterprise cloud	✓	
Advanced Care Planning	✓	
Advanced Reporting	✓	
Interoperability	✓	


Peel & Apply Sensor

- Volume business
- Replaces existing inserted sensor
- Off-the-shelf diapers
- Lower sensor cost
- Lower final assembly and logistics cost



PROXY VOTES RECEIVED





Resolution 1

considering, and if deemed advisable, passing, with or without variation, an ordinary resolution of disinterested shareholders, approving and authorizing, for the purposes of ASX Listing Rule 7.1 and all other purposes, the operation of the conversion mechanism in the Convertible Note Deeds between the Corporation and professional and sophisticated investors, such that the AUD\$1,000,000 non-convertible Debt Notes issued to professional and sophisticated investors becomes AUD\$1,000,000 Convertible Notes (a form of 'equity security' for the purpose of the ASX Listing Rules) on the terms particularly described in the accompanying management information circular

PROXY VOTES RECEIVED

For:	55,648,847	99.94%
Against:	29,444	0.05%
Withheld/ Abstain:	5,127	0.01%
Excluded:	0	
Non Vote:	0	

Resolution 2

considering, and if deemed advisable, passing, with or without variation, an ordinary resolution of disinterested shareholders, approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the operation of the conversion mechanism in the Convertible Note Deed between the Corporation and Dussman Pty. Ltd. (an entity associated with Mr Damien Haakman, a former director of the Corporation and an entity that is considered an insider of the Corporation), such that the AUD\$2,000,000 non-convertible Debt Notes issued to Dussman Pty. Ltd. Become AUD\$2,000,000 Convertible Notes (a form of 'equity security' for the purposes of the ASX Listing Rules) on the terms particularly described in the accompanying management information circular;

PROXY VOTES RECEIVED

For:	17,481,916	99.78%
Against:	34,244	0.20%
Withheld/ Abstain:	5,127	0.03%
Excluded:	38,160,131	
Non Vote:	0	

Resolution 3

considering, and if deemed advisable, passing, with or without variation, an ordinary resolution of disinterested shareholders, approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the operation of the conversion mechanism in the Convertible Note Deed between the Corporation and to Jackham Investments Pty Ltd as trustee for Holland Family Trust (an entity associated with Mr. Craig John Holland, a former Director of the Corporation) such that the AUD\$21,000 non-convertible Debt Notes issued to Jackham Investments Pty Ltd become AUD\$21,000 Convertible Notes (a form of 'equity security' for the purposes of the ASX Listing Rules) on the terms particularly described in the accompanying management information circular;

PROXY VOTES RECEIVED

For:	55,614,047	99.93%
Against:	32,244	0.06%
Withheld/ Abstain:	5,127	0.01%
Excluded:	30,000	
Non Vote:	0	

Resolution 4

considering, and if deemed advisable, passing, with or without variation an ordinary resolution of disinterested shareholders, approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the operation of the conversion mechanism in the Convertible Note Deed between the Corporation and Bingham Investments Pty Ltd as trustee for Bingbird Investments (an entity associated with Mr. Warren Bingham, a Director of the Corporation) such that the AUD\$21,000 non-convertible Debt Notes issued to Bingham Investments Pty Ltd become AUD\$21,000 Convertible Notes (a form of 'equity security' for the purposes of the ASX Listing Rules) on the terms particularly described in the accompanying management information circular;

PROXY VOTES RECEIVED


For:	55,644,047	99.93%
Against:	32,244	0.06%
Withheld/ Abstain:	5,127	0.01%
Excluded:	0	
Non Vote:	0	

Resolution 5

considering, and if deemed advisable, passing, with or without variation, an ordinary resolution of disinterested shareholders, approving and authorizing, for the purposes of the ASX Listing Rule 10.11 and all other purposes, the operation of the conversion mechanism in the Convertible Note Deed between the Corporation and to Michael Brown and Christine Brown as trustees for the Michael Brown Superannuation Fund (an entity associated with Mr. Michael Brown, the former Chairman of the Corporation) such that the AUD\$21,000 non-convertible Debt Notes issued to Michael Brown and Christine Brown become AUD\$21,000 Convertible Notes (a form of 'equity security' for the purposes of the ASX Listing Rules) on the terms particularly described in the accompanying management information circular;

PROXY VOTES RECEIVED

For:	55,642,047	99.93%
Against:	34,244	0.06%
Withheld/ Abstain:	5,127	0.01%
Excluded:	0	
Non Vote:	0	



Resolution 6

considering, and if deemed advisable, passing, with or without variation, an ordinary resolution approving for the purposes of ASX Listing Rule 7.1 the issue to professional and sophisticated investors up to 138,740,000 common shares in the capital of the Corporation in the form of CHES Depository Interests (“CDIs”) at an issue price of AUD\$0.05 per CDI, and otherwise as more particularly described in the accompanying management information circular;

PROXY VOTES RECEIVED

For:	45,739,319	99.91%
Against:	41,571	0.09%
Withheld/ Abstain:	0	0.00%
Excluded:	9,900,528	
Non Vote:	0	

Resolution 7

considering, and if deemed advisable, passing, with or without variation, an ordinary resolution approving for the purposes of ASX Listing Rule 10.11 and all other purposes the grant to Mr Michael Spooner of up to 7,603,422 unlisted options, representing approximately 2.50% of the issued capital post completion (each option on exercise resulting in the issue of 1 fully paid common share in the capital of the Corporation credited as fully paid) with an exercise price of AUD\$0.05 per option and otherwise on the terms summarized in the accompanying management information circular;

PROXY VOTES RECEIVED

For:	54,476,323	98.01%
Against:	995,429	1.79%
Withheld/ Abstain:	109,666	0.20%
Excluded:	0	
Non Vote:	100,000	

Resolution 8

considering, and if deemed advisable, passing, with or without variation, an ordinary resolution approving for the purposes of ASX Listing Rule 10.11 and all other purposes the grant to Dr Gary Pace of up to 7,603,422 unlisted options, representing approximately 2.50% of the issued capital post completion (each option on exercise resulting in the issue of 1 fully paid common share in the capital of the Corporation credited as fully paid) (each option on exercise resulting in the issue of 1 fully paid common share in the capital of the Corporation credited as fully paid) with an exercise price of AUD\$0.05 per option and otherwise on the terms summarized in the accompanying management information circular;

PROXY VOTES RECEIVED

For:	54,576,323	98.02%
Against:	995,429	1.79%
Withheld/ Abstain:	109,666	0.20%
Excluded:	0	
Non Vote:	0	

Resolution 9

considering, and if deemed advisable, passing, with or without variation, an ordinary resolution approving, for the purposes of ASX Listing Rule 10.17 and all other purposes, an increase in the total amount of potential aggregate directors' fees which may be paid to non-executive directors for their services as non-executive directors of the Corporation (the "Non-executive Director Fee Pool"), from AUD\$350,000 to a maximum aggregate amount of AUD\$700,000 per annum, being an increase of the maximum aggregate of AUD\$350,000 per annum, as more particularly described in the accompanying management information circular;

PROXY VOTES RECEIVED

For:	49,405,237	88.73%
Against:	5,840,046	10.49%
Withheld/ Abstain:	433,485	0.78%
Excluded:	0	
Non Vote:	2650	



Questions?

Thank you